2021 Fiscal Year Final Research Report
beta2-adrenoceptor in renal cell carcinoma
| Project/Area Number |
20K18085
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | ADRB / 腎癌 / 薬剤耐性 |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to investigate the role of β-adrenoceptor (ADRB) and drug resistance induced by ADRB activation in renal cell carcinoma (RCC). Adding isoproterenol onto human RCC cells, the phosphorylation of ERK1/2 and Akt was up-regulated, the expression of anti-apoptotic protein BCL2 and MCL1 increased, and the cell viability increased. This reaction was canceled by ADRB2 knockdown, while was not by ADRB1 knockdown. Clinically used RCC therapeutic agents sorafenib and cabozantinib suppressed viability in RCC cell lines, and isoproterenol weakened the sorafenib and cabozantinib effects.
|
| Free Research Field |
泌尿器科
|
| Academic Significance and Societal Importance of the Research Achievements |
ADRB刺激はストレス環境で惹起されることが知られている。ストレス環境が癌の予後を悪化させることは多くの癌腫で報告されているが、その機序に言及したものは少ない。本研究は、ADRB刺激により腎癌の細胞活性をあげ、治療抵抗性に寄与することを基礎研究レベルで解明しており、今後ストレスとの関係などとの関連の研究の礎になると考えられる。
|
